Cargando…

Therapeutical use of probiotic formulations in clinical practice

BACKGROUND & AIMS: The spreading of gastrointestinal diseases is growing all over the world. Although for some of them an effective therapeutic approach has been found, palliation rather than cure is very frequent due to a partial knowledge of their aethiology and pathogenesis. This review, anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannitti, T., Palmieri, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172412/
https://www.ncbi.nlm.nih.gov/pubmed/20576332
http://dx.doi.org/10.1016/j.clnu.2010.05.004
_version_ 1783524252683599872
author Iannitti, T.
Palmieri, B.
author_facet Iannitti, T.
Palmieri, B.
author_sort Iannitti, T.
collection PubMed
description BACKGROUND & AIMS: The spreading of gastrointestinal diseases is growing all over the world. Although for some of them an effective therapeutic approach has been found, palliation rather than cure is very frequent due to a partial knowledge of their aethiology and pathogenesis. This review, analyzing the main clinical studies, aims at being a state of the art update of the use of probiotic formulations in daily practice. METHODS: In this review we include all the most significant clinical trials involving the use of probiotic formulations for the treatment of several pathologies. RESULTS: Dysbiosis has been observed in irritable bowel syndrome patients. Probiotics may exert a beneficial effect on Crohn’s disease affected patients who have shown gut microbiota antigens and altered wall permeability. Moreover some probiotic formulations seem to enhance the therapy for Helycobacter Pylori reducing its pathogenic potential. Intestinal ecology imbalance has been also linked to cancer induction, allergy, skin and urogenital diseases. In addition probiotics administration seems to be particularly useful to ease post-operative complications. CONCLUSION: Further future clinical trials, involving large numbers of patients, will be mandatory to achieve definite evidence of the preventive and curative role of probiotics in medical practice.
format Online
Article
Text
id pubmed-7172412
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
record_format MEDLINE/PubMed
spelling pubmed-71724122020-04-22 Therapeutical use of probiotic formulations in clinical practice Iannitti, T. Palmieri, B. Clin Nutr Review BACKGROUND & AIMS: The spreading of gastrointestinal diseases is growing all over the world. Although for some of them an effective therapeutic approach has been found, palliation rather than cure is very frequent due to a partial knowledge of their aethiology and pathogenesis. This review, analyzing the main clinical studies, aims at being a state of the art update of the use of probiotic formulations in daily practice. METHODS: In this review we include all the most significant clinical trials involving the use of probiotic formulations for the treatment of several pathologies. RESULTS: Dysbiosis has been observed in irritable bowel syndrome patients. Probiotics may exert a beneficial effect on Crohn’s disease affected patients who have shown gut microbiota antigens and altered wall permeability. Moreover some probiotic formulations seem to enhance the therapy for Helycobacter Pylori reducing its pathogenic potential. Intestinal ecology imbalance has been also linked to cancer induction, allergy, skin and urogenital diseases. In addition probiotics administration seems to be particularly useful to ease post-operative complications. CONCLUSION: Further future clinical trials, involving large numbers of patients, will be mandatory to achieve definite evidence of the preventive and curative role of probiotics in medical practice. Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. 2010-12 2010-06-23 /pmc/articles/PMC7172412/ /pubmed/20576332 http://dx.doi.org/10.1016/j.clnu.2010.05.004 Text en Copyright © 2010 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Iannitti, T.
Palmieri, B.
Therapeutical use of probiotic formulations in clinical practice
title Therapeutical use of probiotic formulations in clinical practice
title_full Therapeutical use of probiotic formulations in clinical practice
title_fullStr Therapeutical use of probiotic formulations in clinical practice
title_full_unstemmed Therapeutical use of probiotic formulations in clinical practice
title_short Therapeutical use of probiotic formulations in clinical practice
title_sort therapeutical use of probiotic formulations in clinical practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172412/
https://www.ncbi.nlm.nih.gov/pubmed/20576332
http://dx.doi.org/10.1016/j.clnu.2010.05.004
work_keys_str_mv AT iannittit therapeuticaluseofprobioticformulationsinclinicalpractice
AT palmierib therapeuticaluseofprobioticformulationsinclinicalpractice